Page 41 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel Treatment Approach in Transthyretin Amyloidosis

Novel Treatment Approach in Transthyretin Amyloidosis
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

United statesProthena biosciencesMorie gertzAmerican academy of neurologyOle suhrAmerican academyMedscape medical newsMayo clinicஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல்ஓல் சுஹ்ர்அமெரிக்கன் கலைக்கழகம்மயோ சிகிச்சையகம்

Zogenix, Inc (NASDAQ:ZGNX) - Zogenix s Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder

Zogenix, Inc (NASDAQ:ZGNX) - Zogenix s Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesEuropean medicines agencyAmerican academy of neurologyZogenix incAmerican academyஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல்அமெரிக்கன் கலைக்கழகம்

#AANAM – Ublituximab Reduced MS Relapse Rate, Disability Progression

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’ annualized relapse rates and lowering the number of brain lesions over nearly two years, according to data from the ULTIMATE clinical trials. “The results of the ULTIMATE I and II studies show that not only did ublituximab effectively reduce relapses in patients with RMS, but had a profound effect on suppressing inflammatory activity,” Steinman, the global study chair for the two trials, said in a press release.

Long beachUnited statesStanford universityLawrence steinmanUniversity of lisbonAmerican academy of neurologyBiomedical sciencesColumbia universityMultiple sclerosis news todayteamMolecular biologyUniversidade nova de lisboaManaging science editorநீண்டது கடற்கரைஒன்றுபட்டது மாநிலங்களில்ஸ்டான்போர்ட் பல்கலைக்கழகம்லாரன்ஸ் ஸ்டெய்ன்மேன்

Human IgG1 Antibody Shows Promise in Myasthenia Gravis

email article More patients with myasthenia gravis who were treated with the investigational agent efgartigimod achieved a sustained improvement in a scale of activities of daily living compared with patients who were given placebo, a researcher reported. Of patients with generalized myasthenia gravis and anti-acetylcholine receptor antibody (AChR-Ab) positivity in a phase III study, 67.7% receiving efgartigimod achieved at least a 2-point improvement in their Myasthenia Gravis-Activities of Daily Living (MG-ADL) score after the first cycle of treatment, compared with 29.7% of those receiving placebo ( P

United statesMyasthenia gravis foundation of americaAmerican academy of neurologyPamerican academy of neurologyMyasthenia gravis activitiesDaily livingMyasthenia gravis foundationஒன்றுபட்டது மாநிலங்களில்மியஸெநிய க்ர்யாவிஸ் அடித்தளம் ஆஃப் அமெரிக்காஅமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல்மியஸெநிய க்ர்யாவிஸ் நடவடிக்கைகள்தினசரி வாழும்மியஸெநிய க்ர்யாவிஸ் அடித்தளம்

Long-term Benefit for DBS in Treating Parkinson s Motor Symptoms

Long-term Benefit for DBS in Treating Parkinson s Motor Symptoms
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoAlfonso fasanoJilll ostremUniversity of californiaUniversity of torontoSan francisco movement disordersUs veterans affairs va cooperative study programAmerican academy of neurologyNeuromodulation centerNational institute of neurological disordersMedscape medicalAmerican academyCooperative study programNational instituteNeurological disorders